Price target
5.630.00 0.00%
The 5 analysts offering 1 year price forecasts for 1S9 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 7 analysts giving stock ratings to 1S9 in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
1S9 EPS for the last quarter is −0.24 CHF despite the estimation of −0.31 CHF. In the next quarter EPS is expected to reach −0.26 CHF. Track more of SERES THERAPEUTICS financials and stay on top of what is up with the company.
In the next quarter SERES THERAPEUTICS revenue is expected to reach −207.05 K CHF. Check out SERES THERAPEUTICS revenue and earnings and make informed decisions.
According to analysts, 1S9 price target is 5.63 CHF with a max estimate of 13.63 CHF and a min estimate of 0.91 CHF. Check if this forecast comes true in a year, meanwhile watch SERES THERAPEUTICS stock price chart and keep track of the current situation with 1S9 news and stock market news.
We've gathered opinions of 7 analysts rating 1S9 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.